Q3 2025 Organon & Co Earnings Call Transcript
Key Points
- Organon & Co (OGN) reported third quarter revenue of $1.6 billion and an adjusted EBITDA of $518 million, representing a margin of 32.3%.
- The company's Biosimilars segment showed strong performance, particularly with Hadlima, which saw a 63% increase globally, benefiting from a low-price strategy and recent interchangeability approval in the US.
- Organon & Co (OGN) successfully divested the Jada system for $440 million, with an additional $25 million contingent on 2026 revenue targets, allowing for faster deleveraging.
- The company has a diverse product portfolio, including women's health, Biosimilars, and established brands, which helps generate meaningful revenue and deliver value globally.
- Organon & Co (OGN) is committed to operational excellence and strategic priorities, including deleveraging the business, driving cost savings, and achieving revenue growth.
- The women's health franchise declined by 4% at constant currency, with a notable 9% decline in Nexplanon sales due to unfavorable US policy impacting budget-constrained public segments.
- The respiratory business faced significant challenges, with declines in Singulair and Dulera due to competitive pressures and mandatory price reductions in key markets like Japan and China.
- Organon & Co (OGN) lowered its full-year revenue guidance to $6.2 billion to $6.25 billion, reflecting persisting US policy challenges in Nexplanon and respiratory business issues.
- The company's adjusted gross margin declined year-over-year, primarily due to pricing pressure, unfavorable product mix, and foreign exchange impacts on inventory turns.
- Organon & Co (OGN) is facing challenges in the uptake of Vtama, with the launch curve being flatter than expected, impacting the company's ability to reach its $150 million target for the year.
Hello, and welcome to the Organon Third Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations. You may begin.
Thank you, operator, and good morning, everyone. Today, we will be referencing a presentation that is visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events & Presentations section of our Organon Investor Relations website. Please reference Slides 2 and 3 for some brief reminders.
I would like to caution listeners that certain information discussed by management during this call will include forward-looking statements. Forward-looking statements can be identified because they do not relate strictly to historical or current facts and use words such as potential, should, will, continue, expects, believes, future, estimates, believes and other words of similar meaning.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
